Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03822494 · ClinicalTrials.gov registry record · NA
CyberKnife Dose Escalation Prostate Cancer Trial
A NA study of Prostate Cancer and Prostate Adenocarcinoma, sponsored by Crozer-Keystone Health System.
- Active
- Registry status
- NA
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT03822494: Active NA study of Prostate Cancer and Prostate Adenocarcinoma, sponsored by Crozer-Keystone Health System.
NCT03822494 is a NA study of Prostate Cancer and Prostate Adenocarcinoma that is active but no longer recruiting, run by Crozer-Keystone Health System. The registered enrollment target is 100 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03822494, a NA study of Prostate Cancer and Prostate Adenocarcinoma, is active but no longer recruiting, sponsored by Crozer-Keystone Health System.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
Stereotactic body radiation therapy (SBRT) has been employed in the treatment of prostate cancer. Multiple single institution experiences suggest high biochemical control rates with acceptable toxicity in low risk prostate cancer but efficacy data in unfavorable type prostate cancer is less convincing. CyberKnife-SBRT (CK-SBRT) can be used to escalate radiation dose delivery to the prostate while sparing normal tissue.
Primary Outcome
Genitourinary or Bowel Toxicity as a result of radiation therapy will be reported using
Conditions Studied
Interventions
- RADIATION CyberKnife SBRT
Study Locations (1)
Pennsylvania
- Philadelphia CyberKnife - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2018-07-12 |
| Est. Completion | 2028-07-12 |
| Phase | NA |
What the registry record for NCT03822494 still lists
NCT03822494 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (84% lower).
The record links to 3 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which CyberKnife SBRT is the first listed.
NCT03822494 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03822494 about?
NCT03822494 is a clinical study titled "CyberKnife Dose Escalation Prostate Cancer Trial". Stereotactic body radiation therapy (SBRT) has been employed in the treatment of prostate cancer. Multiple single institution experiences suggest high biochemical control rates with acceptable toxicity in low risk prostate cancer but efficacy data in unfavorable type prostate cancer is less convinci...
What is the current status of trial NCT03822494?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 100 participants. The study started on 2018-07-12. Estimated completion is 2028-07-12.
What conditions does trial NCT03822494 study?
This clinical trial studies the following conditions: Prostate Cancer, Prostate Adenocarcinoma, Prostate Neoplasm.
What interventions are being tested in trial NCT03822494?
The interventions under investigation include: CyberKnife SBRT (RADIATION).
Who is sponsoring clinical trial NCT03822494?
This trial is sponsored by Crozer-Keystone Health System, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03822494 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03822494's enrollment target sits among peer trials
100 330th of 735 higher than 389 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Improving Health Literacy in African-American Prostate Cancer Patients
RECRUITING · NA
-
Pilot Study to Investigate Magnetic Resonance (MR) Image Guided Focal Therapy in Prostate Cancer
RECRUITING · NA
-
Diffusion Basis Spectrum Imaging of the Prostate
RECRUITING · NA
-
Micro-UltraSound In Cancer - Active Surveillance
RECRUITING · NA
-
Precise Oncology Interventions in Nutrition and Training (OnPoint)
RECRUITING · NA
-
SBRT Boost for Unfavorable Prostate Cancer'
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI